In late 2022, the results of a groundbreaking stage-three trial for a ‘miracle’ new Alzheimer’s drug, lecanemab, were hailed as momentous. Finally, for the first time, a drug had slowed the ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The preprint was posted on Research Square and had not been peer-reviewed ...

News of the death of the 65-year-old woman, who was receiving lecanemab as part of the CLARITY-AD trial, first emerged in November shortly after the top-line results from the study were revealed.

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in research because they target a known cause of the disease, rather than just treating ...

Results from the open-label long-term extension study (OLE) following the core study of the lecanemab phase 3 Clarity AD study presented at AAIC in July, showed that the mean change from baseline ...

New research reveals that lecanemab, an Alzheimer's drug previously hailed for slowing disease progression, may increase the risk of death by 25%. The study found a tripled risk of death within a ...

Lars Lannfelt will be one of the keynote speakers at the conference. In addition, BioArctic's partner Eisai present lecanemab data in two oral and one poster presentation at the meeting and three ...

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease ...

and emerging medicines such as lecanemab, which would be particularly costly for the health service to deliver, mean that a new pricing structure is required. A decade ago, Karl Claxton ...